Filing Date Form TypeDescription   
   
2020-05-05DEFR14ARevised definitive proxy soliciting materialsAcc-no: 0001213900-20-010983 (34 Act)  Size: 2 MB
2020-04-29DEF 14AOther definitive proxy statementsAcc-no: 0001213900-20-010436 (34 Act)  Size: 2 MB
2019-04-26DEF 14AOther definitive proxy statementsAcc-no: 0001615774-19-006326 (34 Act)  Size: 783 KB
2018-04-26DEF 14AOther definitive proxy statementsAcc-no: 0001615774-18-002916 (34 Act)  Size: 551 KB


Sensus Healthcare Reports First Quarter 2021 Financial Results
05/06/2021 8:05 PM

Revenues up 83% year-over-year


Sensus Healthcare to Host First Quarter 2021 Financial Results and Business Update Conference Call on May 6, 2021
04/29/2021 8:00 PM

BOCA RATON, Fla. , April 29, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Sensus Healthcare Announces the Sale/Install of its 500th Unit
04/13/2021 12:00 PM

Mid-Atlantic Skin Surgery Institute in Maryland acquires a second SRT system
Mid-Atlantic Skin Surgery Institute in Maryland acquires a second SRT system

Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care
03/16/2021 12:00 PM

Effectiveness and Utility of SRT-100™ Demonstrated in the Companion-Animal Market


Sensus Healthcare to Participate in Three Investment Conferences During the Month of March
03/08/2021 9:15 PM

BOCA RATON, Fla, March 08, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a  medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that Joe Sardano, Chairman and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows:


Sensus Healthcare Reports Fourth Quarter and Full Year 2020 Financial Results
02/25/2021 9:05 PM

Achieves fourth quarter net income of $1.0 million on revenues of $5.1 million


Sensus Healthcare Granted U.S. Patent for Three-Dimensional Beam Forming X-Ray Source
02/23/2021 1:00 PM

Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices
Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices

Sensus Healthcare to Host Fourth Quarter 2020 Financial Results and Business Update Conference Call on February 25, 2021
02/18/2021 1:00 PM

BOCA RATON, Fla, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 25, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Holy Name Medical Center in Teaneck, New Jersey Acquires Sensus Healthcare’s Low-dose Radiation Therapy System to Treat Pneumonia in COVID-19 Patients
01/06/2021 2:32 PM

BOCA RATON, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced Holy Name Medical Center in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for the treatment of pneumonia in COVID-19 patients.


Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems
12/15/2020 1:00 PM

Agreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021
Agreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021

Sensus Healthcare Announces CMS Sets Rates Higher for SRT Reimbursement
12/08/2020 1:00 PM

 BOCA RATON, Fla, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has issued a new, final reimbursement amount for CPT® code 77401 of approximately $41 per treatment.  CPT code 77401 covers the delivery of Superficial Radiation Therapy (SRT) and this new amount represents a 66% increase from current levels.  This is the first meaningful revaluation of CPT code 77401 since 2002.


Sensus Healthcare Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision
12/01/2020 1:00 PM

Prospective study published in Journal of the American Academy of Dermatology


Sensus Healthcare Reports Third Quarter 2020 Financial Results
11/05/2020 9:02 PM

Conference call begins at 4:30 p.m. Eastern time today
Conference call begins at 4:30 p.m. Eastern time today

Sensus Healthcare Appoints Megan Cornish to its Board of Directors
11/05/2020 1:00 PM


Sensus Healthcare to Host Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020
10/29/2020 3:18 PM

BOCA RATON, Fla. , Oct. 29, 2020 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Sensus Healthcare Announces Publication of Study Showing Use of Superficial Radiation Therapy Post-Keloidectomy Prevents Keloid Recurrence
10/22/2020 12:00 PM

BOCA RATON, Fla., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the publication of a retrospective study showing keloidectomy followed by superficial radiation therapy (SRT) had an approximate 10% recurrence rate, compared with an expected recurrence rate of more than 80% following surgical excision alone.  The study was published in the Journal of Clinical and Aesthetic Dermatology and can be found here.  Authors were:


Sensus Healthcare Reports Second Quarter 2020 Financial Results
08/06/2020 8:02 PM

Conference call begins at 4:30 p.m. Eastern time today
Conference call begins at 4:30 p.m. Eastern time today

American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units
08/05/2020 12:30 PM

Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems


Sensus Healthcare Acquires Two Mobile Aesthetic Laser Companies in Florida
08/04/2020 12:30 PM


Sensus Healthcare to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 6, 2020
07/30/2020 12:30 PM

BOCA RATON, Fla. , July 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.